The effects of excipients and particle engineering on the biophysical stability and aerosol performance of parathyroid hormone (1-34) prepared as a dry powder for inhalation

AAPS PharmSciTech

Volumn 12, Issue 1, 2011, Pages 304-311

  Shoyele, Sunday A ^a   Sivadas, Neeraj ^b   Cryan, Sally Ann ^c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b Tullamore Co Offaly   (Ireland)

^c ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

parathyroid hormone; pulmonary delivery; spray drying; spray freeze drying; stability

Indexed keywords

BRIJ 97; EXCIPIENT; NONIONIC SURFACTANT; PARATHYROID HORMONE[1-34]; TREHALOSE; UNCLASSIFIED DRUG;

AEROSOL; ARTICLE; CIRCULAR DICHROISM; DIFFERENTIAL SCANNING CALORIMETRY; DIFFRACTION; DRUG ACTIVITY; DRUG FORMULATION; DRUG STABILITY; DRY POWDER; ELECTRON MICROSCOPY; FLUORESCENCE SPECTROSCOPY; FREEZE DRYING; HUMAN; INHALATIONAL DRUG ADMINISTRATION; PHARMACEUTICAL ENGINEERING; PRIORITY JOURNAL; PROTEIN PROCESSING; SPRAY DRYING;

ADMINISTRATION, INHALATION; AEROSOLS; CIRCULAR DICHROISM; DRUG STABILITY; EXCIPIENTS; FREEZE DRYING; HORMONE REPLACEMENT THERAPY; HUMANS; PARATHYROID HORMONE; PARTICLE SIZE; PEPTIDES; POWDERS; PROTEINS; TREHALOSE;

EID: 79954417523     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-011-9585-2     Document Type: Article

References (28)

1. J Patton 2000 Pulmonary delivery of drugs for bone disorders Adv Drug Deliv Rev 42 3 239 248 10963838 10.1016/S0169-409X(00)00064-8 1:CAS:528:DC%2BD3cXlvV2hsLY%3D (Pubitemid 30645780)
2. E Barrett-Connor 1995 The economic and human costs of osteoporotic fracture Am J Med 98 2A 3S 8S 7709931 10.1016/S0002-9343(05)80037-3 1:STN:280:DyaK2M3isFarug%3D%3D
3. E Quattrocchi H Kourlas 2004 Teriparatide: a review Clin Ther 26 6 841 854 15262455 10.1016/S0149-2918(04)90128-2 1:CAS:528:DC%2BD2cXmsVSisrc%3D (Pubitemid 38943033)
4. JRA Tashjian B Chabner 2002 Commentary on clinical safety of recombinant human parathyroid hormone 1-34 in the treatment of osteoporosis in men and postmenopausal women J Bone Miner Res 17 1151 1161 12096828 10.1359/jbmr.2002. 17.7.1151 1:CAS:528:DC%2BD38XlsF2nurg%3D (Pubitemid 34680490)
5. S Shoyele A Slowey 2006 Prospects of formulating proteins/peptides as aerosols for pulmonary drug delivery Int J Pharm 314 1 1 8 16563674 10.1016/j.ijpharm.2006.02.014 1:CAS:528:DC%2BD28Xjslyjsrc%3D (Pubitemid 44389384)
6. Akers M, Vasudevan V, Stickelmeyer M. Formulation development of protein dosage forms. In: Nail SL, Akers MJ, editors. Development and manufacture of protein pharmaceuticals. New York: Kluwer; 2002. p. 47.
7. M Manning K Patel R Borchardt 1989 Stability of protein pharmaceuticals Pharm Res 6 11 903 918 2687836 10.1023/A:1015929109894 1:CAS:528: DyaK3cXkt1aruw%3D%3D (Pubitemid 20078439)
8. S Kobayashi S Kondo K Juni 1996 Pulmonary delivery of salmon calcitonin dry powders containing absorption enhancers in rats Pharm Res 13 1 80 83 8668684 10.1023/A:1016081301369 1:CAS:528:DyaK28XhtFajsrw%3D (Pubitemid 26076300)
9. A Pfutzner F Flacke R Pohl D Linkie M Engelbach R Woods, et al. 2003 Pilot study with Technosphere/PTH (1-34)-a new approach for effective pulmonary delivery of parathyroid hormone (1-34) Horm Metab Res 35 5 319 323 12916003 10.1055/s-2003-41309 1:STN:280:DC%2BD3sznvFGitg%3D%3D (Pubitemid 37011519)
10. V Codrons F Vanderbist R Verbeeck M Arras D Lison V Préat, et al. 2003 Systemic delivery of parathyroid hormone (1-34) using inhalation dry powders in rats J Pharm Sci 92 5 938 950 12712413 10.1002/jps.10346 1:CAS:528:DC%2BD3sXjs1ehsrw%3D (Pubitemid 36523439)
11. S Shoyele S Cawthorne 2006 Particle engineering techniques for inhaled biopharmaceuticals Adv Drug Deliv Rev 58 9-10 1009 1029 17005293 10.1016/j.addr.2006.07.010 1:CAS:528:DC%2BD28Xht1Sht7vE (Pubitemid 44712022)
12. H Costantino L Firouzabadian C Wu K Carrasquillo K Griebenow S Zale, et al. 2002 Protein spray freeze drying. 2. Effect of formulation variables on particle size and stability J Pharm Sci 91 2 388 395 11835198 10.1002/jps.10059 1:CAS:528:DC%2BD38XhsVSmsrg%3D (Pubitemid 34137360)
13. J Engstrom D Simpson E Lai R Williams III K Johnston 2007 Morphology of protein particles produced by spray freezing of concentrated solutions Eur J Pharm Biopharm 65 2 149 162 17010582 10.1016/j.ejpb.2006.08.005 1:CAS:528:DC%2BD2sXis1ejsg%3D%3D (Pubitemid 46038083)
14. A Hillgren M Aldén 2002 A comparison between the protection of LDH during freeze-thawing by PEG 6000 and Brij 35 at low concentrations Int J Pharm 244 1-2 137 149 12204573 10.1016/S0378-5173(02)00322-8 1:CAS:528: DC%2BD38XmsVahsrY%3D (Pubitemid 35245454)
15. N Jovanovic A Bouchard G Hofland G Witkamp D Crommelin W Jiskoot 2006 Distinct effects of sucrose and trehalose on protein stability during supercritical fluid drying and freeze-drying Eur J Pharm Sci 27 4 336 345 16338123 10.1016/j.ejps.2005.11.003 1:CAS:528:DC%2BD28XotVemtw%3D%3D (Pubitemid 43143259)
16. M Ameri Y Maa 2006 Spray drying of biopharmaceuticals: stability and process considerations Drying Technol 24 6 763 768 10.1080/03602550600685275 1:CAS:528:DC%2BD28Xntl2ks7k%3D (Pubitemid 43820928)
17. J Jeon D Puleo 2008 Formulations for intermittent release of parathyroid hormone (1-34) and local enhancement of osteoblast activities Pharm Dev Technol 13 6 505 512 18720235 10.1080/10837450802282488 1:CAS:528:DC%2BD1cXht1ymsrnE
18. K Johnson 1997 Preparation of peptide and protein powders for inhalation Adv Drug Deliv Rev 26 1 3 15 10837528 10.1016/S0169-409X(97)00506-1 1:CAS:528:DyaK2sXjsVKht7Y%3D (Pubitemid 27288480)
19. Y Maa P Nguyen T Sweeney S Shire C Hsu 1999 Protein inhalation powders: spray drying vs spray freeze drying Pharm Res 16 2 249 254 10100310 10.1023/A:1018828425184 1:CAS:528:DyaK1MXhvFyltr4%3D (Pubitemid 29135129)
20. Z Yu K Johnston R Williams III 2006 Spray freezing into liquid versus spray-freeze drying: Influence of atomization on protein aggregation and biological activity Eur J Pharm Sci 27 1 9 18 16188431 10.1016/j.ejps.2005.08. 010 1:CAS:528:DC%2BD2MXht1Ontb7N (Pubitemid 41728250)
21. D Edwards J Hanes G Caponetti J Hrkach A Ben-Jebria M Eskew, et al. 1997 Large porous particles for pulmonary drug delivery Science 276 5320 1868 9188534 10.1126/science.276.5320.1868 1:CAS:528:DyaK2sXksVCmsr4%3D (Pubitemid 27443665)
22. P Manavalan W Johnson 1985 Protein secondary structure from circular dichroism spectra J Biosci 8 1 141 149 10.1007/BF02703972 1:CAS:528: DyaL28XhvValuro%3D
23. K Kanaori M Takai A Nosaka 2004 Comparative study of chicken and human parathyroid hormone-(1-34)-peptides in solution with SDS Eur J Biochem 249 3 878 885 10.1111/j.1432-1033.1997.00878.x
24. B Demeule M Lawrence A Drake R Gurny T Arvinte 2007 Characterization of protein aggregation: the case of a therapeutic immunoglobulin Biochimica et Biophysica Acta (BBA)-Proteins & Proteomics 1774 1 146 153 10.1016/j.bbapap.2006.10.010 1:CAS:528:DC%2BD2sXltFWktA%3D%3D (Pubitemid 46055309)
25. M Capelle R Gurny T Arvinte 2007 High throughput screening of protein formulation stability: practical considerations Eur J Pharm Biopharm 65 2 131 148 17107777 10.1016/j.ejpb.2006.09.009 1:CAS:528:DC%2BD2sXis1aquw%3D%3D (Pubitemid 46038086)
26. H Costantino L Firouzabadian K Hogeland C Wu C Beganski K Carrasquillo, et al. 2000 Protein spray-freeze drying. Effect of atomization conditions on particle size and stability Pharm res 17 11 1374 1382 11205730 10.1023/A:1007570030368 1:CAS:528:DC%2BD3MXlvFymtQ%3D%3D (Pubitemid 32109489)
27. Lechuga-Ballesteros D. S, L. M., Vehring, R., Kuo M-C (eds). Use of a novel excipient to enable the preparation of stable and dispersible dry powder aerosol formulation by spray drying. In: 30th Annual Meeting and Symposium of the Controlled Release Society, Glasgow, Scotland; 2003
28. H Chan 2006 Dry powder aerosol drug delivery-opportunities for colloid and surface scientists Colloids Surf A 284 50 55 10.1016/j.colsurfa.2005.10.091 (Pubitemid 43870203)